Implanet Stock

Implanet FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Implanet (ALIMP.PA) as of Sep 10, 2026 is 61.34 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 26.14 % — a change of 134.66% (higher).

FCF Conversion

61.34 %

YoY

134.66%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Implanet is 2026 61.34 % . FCF Conversion Rate (FCF/EBITDA) of Implanet was 2025 26.14 % . It decreases by 134.66% higher compared to the previous year.

The Implanet FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
73.34 EUR
Jan 1, 2018
86.04 EUR
Jan 1, 2019
81.26 EUR
Jan 1, 2020
78.70 EUR
Jan 1, 2021
116.00 EUR
Jan 1, 2022
74.27 EUR
Jan 1, 2023
26.14 EUR
Jan 1, 2024
61.34 EUR
The Implanet FCF Conversion history
YEARFCF ConversionYoY
61.34 %+134.66%
26.14 %-64.80%
74.27 %-35.98%
116.00 %+47.40%
78.70 %-3.16%
81.26 %-5.55%
86.04 %+17.32%
73.34 %-16.56%
87.89 %-1.01%
88.78 %-1.97%
90.57 %
Access this data via the Eulerpool API

Implanet Stock analysis

What does Implanet do? Implanet SA is a French company that specializes in the manufacture and distribution of innovative medical products. The company was founded in 2007 by Ludovic Lastennet and Rémi Boyer and is headquartered in Bordeaux, France. Implanet's business model focuses on the development, production, and marketing of medical implants and instruments to support orthopedic surgeries. The company works closely with leading surgeons and healthcare facilities to find the ideal solution for patient needs. One of Implanet's main areas of expertise is the spine. The company develops various implantable products for the treatment of degenerative diseases such as scoliosis. Another important area for Implanet is orthopedics, where the company develops solutions for joint problems like knee or hip replacements. The company also creates customized implants tailored to each individual patient for maximum accuracy and effectiveness. A key aspect of Implanet's business model is adapting its products to meet customer requirements. The company collaborates closely with its customers to meet their specific needs and deliver the best possible solution. Implanet is committed to developing innovative solutions that align with surgeons' capabilities and cater to their needs. Implanet maintains partnerships and distribution agreements worldwide to sell its products and achieve market gains. The company distributes its products in the US, Europe, and Asia. To further expand its presence in these markets, Implanet collaborates closely with healthcare organizations and surgeons to ensure its products remain up-to-date and meet customer needs. Implanet strives to develop innovative solutions that revolutionize orthopedics and spine care. The company has already achieved significant success in the past with its Jazz technology, which serves as an excellent example of how the company operates in a customer-oriented and innovative manner. The Jazz technology is an implant designed for scoliosis treatment and is customized to each individual patient. Overall, Implanet has developed an innovative and customer-oriented business model that focuses on continuous product development and collaboration with surgeons and healthcare organizations. With a strong presence in the global market and a range of innovative products, the company positions itself as one of the leading providers in the field of spine care and orthopedics. Implanet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Implanet stock

FCF Conversion Rate (FCF/EBITDA) of Implanet is 61.34 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Implanet changed from 26.14 % to 61.34 %, representing a 134.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Implanet since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Implanet with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Implanet

All Key Metrics — Implanet